Revisiting nanomedicine design strategies for follow-on products: A model-informed approach to optimize performance
Journal of Controlled Release · 2024-12 · 376 · 1251-1270
DOI: 10.1016/j.jconrel.2024.11.004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Controlled Release, 2024-12. Verfasst von Shakti Nagpal und 3 weiteren Autor:innen. Beteiligte Einrichtung: National University of Singapore, Faculty of Science, Department of Pharmacy and Pharmaceutical Sciences, Singapore. Hauptthemen laut MEDLINE: Nanomedicine. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 136 Literaturangaben. Gefördert von: National University of Singapore, Ministry of Education - Singapore.
Abstract (Originalsprache)
The field of nanomedicine is undergoing a seismic transformations with the rise of nanosimilars, reshaping the pharmaceutical landscape and expanding beyond traditional innovators and generic manufacturers. Nanodrugs are increasingly replacing conventional therapies, offering improved efficacy and safety, while the demand for follow-on products drives market diversification. However, the transition from preclinical to clinical stages presents challenges due to the complex biopharmaceutical behavior of nanodrugs. This review highlights the integration of Quality-by-Design (QbD), in vitro-in vivo correlations (IVIVCs), machine learning, and Model-Informed Drug Development (MIDD) as key strategies to address these complexities. Additionally, it discusses the role of high-throughput processes in the optimization of the nanodrug development pipelines. Covering generations of delivery systems from liposomes to RNA-loaded nanoparticles, this review underscores the evolving market dynamics driven by recent advances in nanomedicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National University of Singapore, Faculty of Science, Department of Pharmacy and Pharmaceutical Sciences, Singapore.
- University of Nottingham, Faculty of Science, School of Pharmacy, United Kingdom.
- National University of Singapore, Department of Surgery, Yong Loo Lin School of Medicine, Singapore 119228, Singapore; Cardiovascular Research Institute, National University Heart Centre Singapore, 14 Medical Drive, Sin…
- National University of Singapore, Faculty of Science, Department of Pharmacy and Pharmaceutical Sciences, Singapore. Electronic address: matthias.g.wacker@nus.edu.sg.
Förderung
- National University of Singapore
- Ministry of Education - Singapore
Zitieren
APA
Nagpal, S., Palaniappan, T., Wang, J. W., & Wacker, M. G. (2024). Revisiting nanomedicine design strategies for follow-on products: A model-informed approach to optimize performance. Journal of Controlled Release, 376, 1251-1270. https://doi.org/10.1016/j.jconrel.2024.11.004
Vancouver
Nagpal S, Palaniappan T, Wang JW, Wacker MG. Revisiting nanomedicine design strategies for follow-on products: A model-informed approach to optimize performance. Journal of Controlled Release. 2024;376:1251-1270. doi:10.1016/j.jconrel.2024.11.004
BibTeX
@article{Nagpal2024,
author = {Nagpal, Shakti and Palaniappan, Thilagavathi and Wang, Jiong-Wei and Wacker, Matthias G},
title = {Revisiting nanomedicine design strategies for follow-on products: A model-informed approach to optimize performance},
journal = {Journal of Controlled Release},
year = {2024},
volume = {376},
pages = {1251--1270},
doi = {10.1016/j.jconrel.2024.11.004}
}
EUVIMED